Skip to main content

Advertisement

Table 4 Cost-Effectiveness analysis results

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

  GEM-E GEM
(n = 1,331) (n = 2,936)
Effectiveness 325.6 days 305.6 days
(Overall mean survival time) (0.894 year) (0.839 year)
Incremental Effectiveness 20 days -
(0.055 year)
Costa USD 23,819.51 USD 19,927.98
Incremental Cost USD 3,891.53 -
Incremental Cost-Effectiveness Ratio (ICER) USD 70,755.06/year -
  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
  2. aAverage 2013 exchange rate: one US dollar (USD) = 1,113.85 Korea Won (KRW)